Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (6839)	7/29/1998 2:37:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

I agree with you but not only for XOMA. Why do any deal with any of the biotechs? It seems like it would be cheaper to just buy them up. Unless, and I believe this is the case, the deals are done on such favorable terms to the big pharmas that there is no need to clutter up ones company with an extra layer of management and staff that it is costly or messy to remove. BTW, new patent re BPI and gram positive bacteria. It is a continuation of a previous patent and obviously the stock is doing so well that there is no need to try to make the market aware of this old information. <g> United States Patent 5,783,561 Horwitz, et. al. Jul. 21, 1998 Anti-gram-positive bacterial methods and materials Inventors: Horwitz; Arnold (Los Angeles, CA); Lambert, Jr.; Lewis H. (Fremont, CA); Little, II; Roger G. (Benicia, CA). Assignee: XOMA Corporation (Berkeley, CA). Appl. No.: 758,116 Filed: Nov. 25, 1996